Hypoplastic Left Heart Syndrome
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
LongeveronMIAMI, FL
2 programs1
1
Lomecel-B medicinal signaling cellsPhase 21 trial
Allo-hMSCsPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
LongeveronLomecel-B medicinal signaling cells
LongeveronAllo-hMSCs
Clinical Trials (2)
Total enrollment: 45 patients across 2 trials
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Start: Jun 2021Est. completion: Aug 202640 patients
Phase 2Active Not Recruiting
Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome
Start: Apr 2015Est. completion: Mar 20195 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space